Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges [Yahoo! Finance]
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: Yahoo! Finance
The company is now primarily focused on four core therapeutic areas (cardiovascular diseases, oncology, immunology and neurology & rare diseases). In 2023, Bayer advanced its pipeline with eight investigational new drug (IND) applications. Four assets are expected to advance to phase II by the end of 2024. The company reported consistently positive top-line data on the pipeline candidate elinzanetant across three phase III studies, OASIS 1, 2 and 3. The candidate is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist in development as an oral, once-daily, non-hormonal treatment of moderate to severe vasomotor symptoms associated with menopause. Bayer will submit data from these studies to regulatory bodies and expects to launch the drug in 2025. Elinzanetant is a key candidate in Bayer's pipeline. The successful development and commercialization of elinzanetant is imperative to Bayer, given the recent setbacks. The key drug Nubeqa maintains momentum in prostate cancer
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN) [Yahoo! Finance]Yahoo! Finance
- Seed Paper Bags Bloom as Eco-Conscious Consumers Drive Market to $213.2 Million by 2034 | Future Market Insights, Inc. [Yahoo! Finance]Yahoo! Finance
- Missouri House backs legal shield for weedkiller maker facing thousands of cancer-related lawsuits [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Missouri House backs legal shield for weedkiller maker facing thousands of cancer-related lawsuits [Yahoo! Finance]Yahoo! Finance
- Judge slashes $857 mln Monsanto verdict to $438 mln in PCBs case [Reuters]Reuters